Summary
During the 18 year period 1972-1989 a total of 62 cases of agranulocytosis associated with the use of sulphasalazine were reported to the Swedish Adverse Drug Reactions Advisory Committee (SADRAC).
The median age of the patients was 52 y and median duration of sulphasalazine treatment was 43 days. The fatality rate was 6.5 %, and among patients who recovered the median recovery time was 10 days. Twelve patients were treated concomitantly with other drugs generally suspected to induce agranulocytosis. From sales and prescription data the average incidence of agranulocytosis during sulphasalazine therapy was estimated to be 1/1750 patient years of exposure. From an ongoing Prescription Monitoring Project in a Swedish county it was possible to calculate the proportion of patients receiving sulphasalazine for different periods of time. The incidence of agranulocytosis during the first 30 days was estimated to be 1/2400 patients, while it was 1/700 between Days 31–90 and 1/11200 during Days 91–365.
The risk of developing agranulocytosis during sulphasalazine treatment is considerable during the first three months of treatment, and the traditional way of expressing the risk (1/1750 patient years) underestimates the risk for the individual patient.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pullar T, Hunter JA, Capell HA (1983) Sulfasalazine in rheumatoid arthritis: a double blind comparison of sulfasalazine with placebo and sodium aurothiomalate. Br Med J 287:1096–1099
Jacobson IM, Kelsey PB, Blyden GT, Demirjian AN, Isselbacher KJ (1985) Sulfasalazine-induced agranulocytosis. Am J Gastroenterology 80:118–121
Derry CL, Schwinghammer TL (1988) Agranulocytosis associated with sulfasalazine. Drug Intell Clin Pharm 22:139–142
Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B (1986) Sulfasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J 293: 418–423
Marabani M, Madhos R, Capell HA, Hunter JA (1989) Leucopenia during sulfasalazine treatment for rheumatoid arthritis. Ann Rheum Dis 48:505–507
Kromann-Andersen H (1987) Bivirkninger under brug of salazosulfapyridin (sulfasalazin) i Danmark i perioden 1968–1987. Videnskab og Praksis 149/52: 3557–3559
Drug Sales Statistics in Sweden (Annual publ) National Corporation of Swedish Pharmacies (Apoteksbolaget). S-10514 Stockholm, Sweden
Boethius G, Wiman F (1977) Recording of drug prescription in the county of Jämtland, Sweden I. Methodological aspects. Eur J Clin Pharmacol 12:31–35
Heimpel H (1988) Drug-induced agranulocytosis. Adverse drug experience review. Med Toxicol 3:4491–462
Hörnsten P, Keisu M, Wiholm BE (1990) The incidence of agranulocytosis during treatment of Dermatitis Herpetiformis with dapsone as reported in Sweden 1969–1988. Arch Dermatol 26: 919–922
The International Agranulocytosis and Aplastic Anaemia Study. (1988) Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. Br Med J 297: 262–267
Keisu M, Ekman E, Wiholm B-E (1992) Comparing risk estimates of sulfa induced agranulocytosis from the Swedish spontaneous reporting system and a case-control study. Eur J Clin Pharmacol 43: 211–214
Arneborn P, Palmblad J (1982) Drug-induced neutropenia. A survey for Stockholm 1973–1978. Acta Med Scand 212:289–292
The International Agranulocytosis and Aplastic Anemia Study (1986) Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256:1749–1757
The International Agranulocytosis and Aplastic Anemia Study (1989) Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. Arch Intern Med 149: 1036–1040
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keisu, M., Ekman, E. Sulfasalazine associated agranulocytosis in Sweden 1972–1989. Eur J Clin Pharmacol 43, 215–218 (1992). https://doi.org/10.1007/BF02333012
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02333012